Expanding indications for statins in cerebral ischemia: a quantitative study.

BACKGROUND New US Food and Drug Administration labeling in 2003 recognizes stroke and evidence of cerebrovascular disease as indicator conditions for initiating statin (simvastatin) therapy, based on results of the Heart Protection Study, thereby extending the indications for statins in stroke beyond current US and European guidelines. OBJECTIVE To assess the impact on clinical practice of broadening indications for statins in patients with stroke. DESIGN Observational study. SETTING University hospital stroke service. PATIENTS One hundred consecutive patients with ischemic stroke and transient ischemic attack. INTERVENTIONS Development and application of algorithms for initiating statin therapy in patients with stroke and transient ischemia abstracted from recent national and international guidelines (National Cholesterol Education Program Adult Treatment Panel III, European Joint Task Force II), Heart Protection Study entry criteria, and Heart Protection Study-based US Food and Drug Administration labeling. MAIN OUTCOME MEASURES Percentages of patients who met clinical trial-validated and US Food and Drug Administration-approved criteria for initiation of statin therapy. RESULTS Patient age averaged 74 years (range, 35-96 years); 64% were female, and 74% were white. Stroke subtype was large-vessel atherosclerosis in 24%, cardioembolic in 44%, small-vessel atherosclerosis in 22%, and other in 10%. Twenty of 100 patients were already taking statins on admission. Guidelines for definite initiation of statin treatment were met by 48% of patients for the National Cholesterol Education Program III, 38% for the European Joint Task Force II, 92% for the Heart Protection Study, and 100% for the Food and Drug Administration. CONCLUSIONS Most clinically encountered patients with ischemic stroke meet clinical trial-validated criteria for initiation of statin therapy. Rigidly applying current national and international guidelines may deprive up to one half of these patients of advantages of statin therapy.

[1]  G. Moneta.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions Heart , 2022 .

[2]  J. Saver,et al.  PROTECT: A coordinated stroke treatment program to prevent recurrent thromboembolic events , 2004, Neurology.

[3]  R. Collins,et al.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.

[4]  S. Grundy,et al.  Clinical Management of Metabolic Syndrome: Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on Scientific Issues Related to Management , 2004, Circulation.

[5]  L. Goldstein,et al.  Prevention and health services delivery. , 2003, Stroke.

[6]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[7]  M. Hennerici,et al.  Design and Baseline Characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study , 2003, Cerebrovascular Diseases.

[8]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[9]  J. Debatin,et al.  Detection of atherosclerosis: systemic imaging for systemic disease with whole-body three-dimensional MR angiography--initial experience. , 2003, Radiology.

[10]  J. Corvol,et al.  Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. , 2003, Archives of internal medicine.

[11]  M. Müllner,et al.  Determination of Lipid Profiles and Use of Statins in Patients With Ischemic Stroke or Transient Ischemic Attack , 2003, Stroke.

[12]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[13]  S. Straus,et al.  New evidence for stroke prevention: clinical applications. , 2002, JAMA.

[14]  D. Leys,et al.  HYPOLIPEMIC AGENTS FOR STROKE PREVENTION , 2002, Clinical and experimental hypertension.

[15]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[16]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[17]  P. Sterzer,et al.  Pravastatin Improves Cerebral Vasomotor Reactivity in Patients With Subcortical Small-Vessel Disease , 2001, Stroke.

[18]  M. Denke,et al.  Defining and treating the metabolic syndrome: A primer from the Adult Treatment Panel III , 2001, Current treatment options in cardiovascular medicine.

[19]  C. Hennekens.  Current perspectives on lipid lowering with statins to decrease risk of cardiovascular disease , 2001, Clinical Cardiology.

[20]  I. Kronzon,et al.  Embolism from the aorta: Atheroemboli and thromboemboli , 2001, Current treatment options in cardiovascular medicine.

[21]  A. Gawlinski,et al.  Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). , 2001, The American journal of cardiology.

[22]  Valentin Fuster,et al.  Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences , 2001, Annals of Internal Medicine.

[23]  A. Gil-Núñez,et al.  Prevention of Brain Ischemia: Controversies and Perspectives , 2001 .

[24]  J. Alger,et al.  Impact on stroke subtype diagnosis of early diffusion-weighted magnetic resonance imaging and magnetic resonance angiography. , 2000, Stroke.

[25]  S M Grundy,et al.  Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 1999, Circulation.

[26]  S. Ross,et al.  Clinical outcomes in statin treatment trials: a meta-analysis. , 1999, Archives of internal medicine.

[27]  E. Ferrari,et al.  Atherosclerosis of the thoracic aorta and aortic debris as a marker of poor prognosis: benefit of oral anticoagulants. , 1999, Journal of the American College of Cardiology.

[28]  A. Folsom,et al.  Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. , 1999, Stroke.

[29]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[30]  J. Papadakis,et al.  Lipids and stroke: neglect of a useful preventive measure? , 1998, Cardiovascular research.

[31]  G. Mancia,et al.  Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.

[32]  Ian Graham,et al.  Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. , 1998, European heart journal.

[33]  R. Westendorp,et al.  Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. , 1997, Stroke.

[34]  David Schultz,et al.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.

[35]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[36]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[37]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[38]  C. Furberg,et al.  Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. , 1994, Circulation.

[39]  K. Asplund,et al.  Factors influencing admission blood pressure levels in patients with acute stroke. , 1991, Stroke.

[40]  P. Wilson,et al.  Coronary risk prediction in adults (the Framingham Heart Study) , 1987, The American journal of cardiology.

[41]  W. Kannel,et al.  A general cardiovascular risk profile: the Framingham Study. , 1976, The American journal of cardiology.